Skip to main
SKIN

SKIN Stock Forecast & Price Target

SKIN Analyst Ratings

Based on 4 analyst ratings
Hold
Strong Buy 25%
Buy 0%
Hold 75%
Sell 0%
Strong Sell 0%

Bulls say

Beauty Health has demonstrated a strong revenue performance in 4Q23, achieving $96.8 million, which surpassed earlier estimates and reflects a positive momentum driven by robust consumable sales. The company's average selling price (ASP) for total systems saw an impressive quarter-over-quarter growth of approximately 20%, reaching $28.8K, indicating an improved sales mix with a higher percentage of direct sales compared to prior periods. Additionally, the company's initial EBITDA guidance, while back-end weighted, aligns favorably above previous market expectations, suggesting potential for enhanced financial performance in future quarters.

Bears say

The Beauty Health Company reported a significant decline in new core delivery system placements, with a drop of over 30% year-over-year and quarter-over-quarter, coming in at 1,210 placements, which was notably below expectations. This deceleration in new system growth raises concerns about future consumables sales, essential for meeting profitability goals in 2024, despite strong performance in consumables during the fourth quarter of 2023. Furthermore, management's guidance for first-quarter 2024 indicated sales of $80 million and an adjusted EBITDA of negative $7.5 million, falling short of previous estimates and implying a challenging path to achieving the full-year EBITDA target of over $40 million.

SKIN has been analyzed by 4 analysts, with a consensus rating of Hold. 25% of analysts recommend a Strong Buy, 0% recommend Buy, 75% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of The Beauty Health Company and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About The Beauty Health Company (SKIN) Forecast

Analysts have given SKIN a Hold based on their latest research and market trends.

According to 4 analysts, SKIN has a Hold consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

The Beauty Health Company (SKIN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.